To interview a Koch Institute investigator, contact 617-324-7795 or ki-communications@mit.edu.
Nano-based drugs, cancer immunology, gene therapy, nanoparticulate drug delivery, and biomaterials
Biomaterials, biomolecular materials and organic-inorganic interfaces processing, biotechnology, nanotechnology, biomolecular engineering
Using micro- and nanotechnology tools to repair damaged tissues, regenerative medicine and tissue biology, nanobiotechnology, biomaterials, extracellular matrix, tissue engineering, therapeutic technologies, infectious disease modeling
Immunology, immunotherapy, protein engineering, T cell recognition, molecular recognition, molecular diversity
T cell response to cancer, mouse model of human lymphoma, immunological memory, influenza, siRNA therapeutics, anti-virals, humanized mouse model
MEMS devices for diagnostics and drug delivery, high throughput systems for pharmaceutical formulation discovery, materials in health sciences
cancer biology, developmental biology, genetics, cell biology, cytoskeletal control of guided cell movement
Multi-agent cancer drug delivery, targeted nanoparticle delivery, combination cancer imaging and delivery systems, stimuli-responsive cancer drug release, thin film release from implants
Cancer biology, genetics, molecular medicine and human disease
Genetics, zebrafish, zebrafish as a model system for cancer, cancer genes, essential genes, animal development and cancer
Molecular genetics, molecular basis of erythroid differentiation, acquired resistance to chemotherapy, molecular medicine and human disease
Cell adhesion, angiogenesis, metastasis, tumor microenvironment, mouse models of human diseases (cancer, inflammation, thrombosis, hemostasis)
Immunotherapy, tumor immunology, drug delivery, nanoparticles, vaccines, leukocyte migration and trafficking
Cancer genetics, cancer biology, mouse models, metastasis, immuno-oncology, molecular medicine, gene targeting technology
Personalized medicine, B-cell lymphomas, Glioblastoma, Lung cancer, Prostate cancer, Deregulation of transcription in cancer
Engineered biomaterials, BioMEMS, tumor targeting, drug delivery, nanoparticles, tissue engineering
Single-cell analysis, immunology, biomanufacturing, immune monitoring in autoimmunity, infectious disease, cancer, allergy
Cell cycle control, molecular medicine and human disease, cell biology, tumor suppressor genes, mammalian and zebrafish models
BioMEMS, microfluidics, biomolecular detection, single cell analysis
Extracellular matrix and signal transduction, cell surface, therapeutics development and delivery, computational modeling of biological and physiological systems, nanotechnology, bioinformatics
RNA interference, gene expression, gene silencing, gene regulation, short RNAs, microRNAs, siRNAs as therapeutics against brain and ovarian cancers, retroviral vectors, alternative splicing, regulation of transcription, nanoparticles and cancer
yeast genetics, cell cycle, cell division, cytoskeleton, protein folding, morphogenesis
Immunology, Immunotherapy, T cell inflammation, adoptive T cell transfer, immune escape, immunotherapy resistance, checkpoint blockades, neoantigens
Cancer metabolism, cancer therapy, host metabolism, pyruvate kinase
Gene transfer and cloning, metastasis, ras oncogenes, tumor growth factor-beta receptors, retinoblastoma, tumor suppressor genes, mouse models of human familial cancers, angiogenesis, telomerase, cell cycle clock
Proteomics, cellular signaling networks, mass spectrometry, receptor tyrosine kinases, ErbB, insulin signaling/resistance
Protein engineering, antibody engineering, tumor targeting, vaccine development, biopharmaceutical pharmacokinetics
Cell signaling and signal transduction, DNA damage, cancer chemotherapy and drug resistance, protein kinases, phospho-binding domains, cell injury, inflammation, neutrophils
Stem cells, organoids, colorectal cancer, obesity
Koch Institute for Integrative Cancer Research
Massachusetts Institute of Technology
500 Main Street, Building 76
Cambridge MA, 02139-4307
617-253-6403